Trial · NCT03287960
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) | Setmelanotide (Entire Study) | 45.5 | 90% Confidence Interval 19.96 to 72.88 | percentage of participants | |
| Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal + Supplemental Cohort) | Setmelanotide (Entire Study) | 53.3 | 90% Confidence Interval 30.00 to 75.63 | percentage of participants | |
| Mean Percent Change From Baseline in Body Weight | Setmelanotide (Entire Study) | -12.34 | Standard Deviation 7.534 | Percent change | |
| Mean Percent Change From Baseline in Hunger Score ('Most Hunger') | Setmelanotide (Entire Study) | -42.7 | Standard Deviation 27.49 | Percent Change | |
| Percentage of Participants Achieving at Least 25% Improvement in Daily Hunger From Baseline | Setmelanotide (Entire Study) | 71.4 | 90% Confidence Interval 46.00 to 89.60 | percentage of participants | |
| Absolute Change From Baseline in Waist Circumference | Setmelanotide (Entire Study) | Baseline | 131.58 | Standard Deviation 24.047 | Centimeter |
| Absolute Change From Baseline in Waist Circumference | Setmelanotide (Entire Study) | Change at Week 52 | -9.80 | Standard Deviation 6.095 | Centimeter |
| Absolute Change in Body Weight (Reversal of Weight Loss) During Double-Blind Placebo-Controlled Withdrawal Period | Setmelanotide (Double-Blind) | Change at Week 4: Setmelanotide | -1.2 | Standard Deviation 3.04 | Kilogram |
| Absolute Change in Body Weight (Reversal of Weight Loss) During Double-Blind Placebo-Controlled Withdrawal Period | Setmelanotide (Double-Blind) | Change at Week 4: Placebo | 4.9 | Standard Deviation 2.82 | Kilogram |
| Absolute Daily Hunger Reduction Score During the Double-Blind Placebo-Controlled Withdrawal Period | Setmelanotide (Double-Blind) | Setmelanotide | 3.4 | Standard Deviation 1.63 | units on a scale |
| Absolute Daily Hunger Reduction Score During the Double-Blind Placebo-Controlled Withdrawal Period | Setmelanotide (Double-Blind) | Placebo | 6.3 | Standard Deviation 2.13 | units on a scale |
| Mean Percent Change From Baseline in Body Mass Index | Setmelanotide (Entire Study) | -14.24 | Standard Deviation 9.096 | Percent change | |
| Change From Baseline in Glucose Parameters | Setmelanotide (Entire Study) | Baseline | 5.586 | Standard Deviation 2.3740 | millimole per liter |
| Change From Baseline in Glucose Parameters | Setmelanotide (Entire Study) | Change at Week 52 | -0.465 | Standard Deviation 1.4350 | millimole per liter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03287960/results